Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-04 DOI:10.1080/14737167.2024.2410963

Mitsuhiro Nagano, Sachiko Hyokai, Kanae Togo, Tendai Mugwagwa, Akira Yuasa

{"title":"Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes.","authors":"Mitsuhiro Nagano, Sachiko Hyokai, Kanae Togo, Tendai Mugwagwa, Akira Yuasa","doi":"10.1080/14737167.2024.2410963","DOIUrl":null,"url":null,"abstract":"Background: In Japan, medical expenses for COVID-19 treatment transitioned from full public funding support to out-of-pocket (OOP) payment by patients plus partial public support in October 2023, and public support fully ended in March 2024. This study evaluated the clinical and economic impacts of initiating OOP payments.Research design and methods: To assess the impact on prescription rates, we compared the prescription rates of antivirals from the 4-month pre- to post-OOP payment initiation period using a claims database. Subsequently, a budget impact model assessed the impacts of a hypothetical decline in the prescription rates on COVID-19-related hospitalizations, deaths, and direct medical costs for antiviral prescription and hospitalization.Results: The antiviral prescription rate per 100 patients decreased from 17.5 for the pre-OOP payment initiation period to 11.5 for the post-OOP payment initiation period, that is, a change of - 34.3%. With prescription rate decreases of 40%, 60%, and 80%, the hospitalizations would increase annually by 22,533 (3.3%), 33800 (5.0%), and 45,066 (6.6%), respectively. The total costs would increase by JPY9.5 billion (USD67.3 million; 0.7%), JPY14.3 billion (USD100.9 million; 1.0%), and JPY19.0 billion (USD134.5 million; 1.3%), respectively.Conclusions: Higher OOP payment decreased the antiviral prescription rate, potentially leading to clinical and economic loss.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2410963","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In Japan, medical expenses for COVID-19 treatment transitioned from full public funding support to out-of-pocket (OOP) payment by patients plus partial public support in October 2023, and public support fully ended in March 2024. This study evaluated the clinical and economic impacts of initiating OOP payments.

Research design and methods: To assess the impact on prescription rates, we compared the prescription rates of antivirals from the 4-month pre- to post-OOP payment initiation period using a claims database. Subsequently, a budget impact model assessed the impacts of a hypothetical decline in the prescription rates on COVID-19-related hospitalizations, deaths, and direct medical costs for antiviral prescription and hospitalization.

Results: The antiviral prescription rate per 100 patients decreased from 17.5 for the pre-OOP payment initiation period to 11.5 for the post-OOP payment initiation period, that is, a change of - 34.3%. With prescription rate decreases of 40%, 60%, and 80%, the hospitalizations would increase annually by 22,533 (3.3%), 33800 (5.0%), and 45,066 (6.6%), respectively. The total costs would increase by JPY9.5 billion (USD67.3 million; 0.7%), JPY14.3 billion (USD100.9 million; 1.0%), and JPY19.0 billion (USD134.5 million; 1.3%), respectively.

Conclusions: Higher OOP payment decreased the antiviral prescription rate, potentially leading to clinical and economic loss.

查看原文本刊更多论文

患者治疗 COVID-19 的经济负担对抗病毒处方率以及临床和经济结果的影响。

背景：在日本，COVID-19治疗的医疗费用于2023年10月从全部公共资金支持过渡到患者自付（OOP）加部分公共支持，公共支持于2024年3月完全终止。本研究评估了启动 OOP 支付的临床和经济影响：为了评估对处方率的影响，我们使用索赔数据库比较了启动 OOP 支付前和启动 OOP 支付后 4 个月的抗病毒药物处方率。随后，预算影响模型评估了处方率假设下降对 COVID-19 相关住院、死亡人数以及抗病毒药物处方和住院直接医疗费用的影响：结果：每 100 名患者的抗病毒处方率从 OOP 开始付费前的 17.5 降至 OOP 开始付费后的 11.5，即变化了 34.3%。如果处方率下降 40%、60% 和 80%，每年的住院人次将分别增加 22,533 人次（3.3%）、33,800 人次（5.0%）和 45,066 人次（6.6%）。总费用将分别增加 95 亿日元（6,730 万美元；0.7%）、143 亿日元（1.009 亿美元；1.0%）和 190 亿日元（1.345 亿美元；1.3%）：结论：较高的 OOP 费用降低了抗病毒处方率，可能导致临床和经济损失。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.